Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GenSight Biologics : Reports Validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

11/03/2020 | 01:31am EST

Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that the LUMEVOQ® Marketing Authorisation Application (MAA) passed the validation checks required for submissions to the European Medicines Agency (EMA), triggering the official start of the MAA review procedure. The application for use of LUMEVOQ® gene therapy to treat vision loss in patients with Leber Hereditary Optic Neuropathy (LHON) due to a mutated ND4 mitochondrial gene was submitted in September, and the procedure was formally initiated on October 29.

“We are delighted that the formal review is now underway and look forward to clarifying any questions that the EMA’s scientific committees may have, commented Bernard Gilly, Co-founder and Chief Executive Officer of GenSight. “Meanwhile, we continue apace with our commercial preparations to ensure that LUMEVOQ® becomes available to LHON patients at the earliest possible time.”

LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new ND4 LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.

Lenadogene nolparvovec (tradename: LUMEVOQ®) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which was specifically developed for the treatment of LHON associated with mutation in the ND4 gene. GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase I/IIa study (CLIN-01), two pivotal Phase III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection), supported by a statistics-based indirect comparison methodology to establish the gene therapy’s efficacy compared to natural history.

The next major administrative milestone step in the review is a pause at Day 120, at which point the Committee for Advanced Therapies will issue a first round of questions and the Company responds as well as submitting information that had been pre-agreed with the agency.

The Company is also working towards submitting LUMEVOQ®’s Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in H2 2021.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

About LUMEVOQ® (GS010; lenadogene nolparvovec)

LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. “LUMEVOQ” was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

About Leber Hereditary Optic Neuropathy (LHON)

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 1,400 to 1,500 new patients who lose their sight every year in the United States and Europe.


© Business Wire 2020
All news about GENSIGHT BIOLOGICS S.A.
04:52aGENSIGHT BIOLOGICS S A : Corporate presentation, January 2021
PU
01/14GENSIGHT BIOLOGICS S A : - ESSA Pharma Announces Clinical Collaboration with Jan..
AQ
01/13GENSIGHT BIOLOGICS S A : Expects EU Decision on Eye Disorder Drug Lumevoq in Q4
MT
01/13GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® RESCUE Pivot..
BU
2020GENSIGHT BIOLOGICS S A : Announces Publication of Results from LUMEVOQ REVERSE P..
AQ
2020GENSIGHT BIOLOGICS : Announces the Partial Conversion of Convertible Bonds and F..
BU
2020GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® REVERSE Pivo..
BU
2020GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
2020GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
2020GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
More news
Financials
Sales 2020 11,5 M 13,8 M 13,8 M
Net income 2020 -19,6 M -23,6 M -23,6 M
Net cash 2020 6,05 M 7,30 M 7,30 M
P/E ratio 2020 -14,5x
Yield 2020 -
Capitalization 352 M 426 M 425 M
EV / Sales 2020 30,2x
EV / Sales 2021 24,4x
Nbr of Employees 25
Free-Float 95,4%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 13,00 €
Last Close Price 8,25 €
Spread / Highest target 81,8%
Spread / Average Target 57,6%
Spread / Lowest Target 21,2%
EPS Revisions
Managers and Directors
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.15.71%426
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458